Humacyte (NASDAQ:HUMA) Cut to Sell at Wall Street Zen

Humacyte (NASDAQ:HUMA - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday.

A number of other brokerages have also weighed in on HUMA. HC Wainwright assumed coverage on Humacyte in a research note on Wednesday, May 14th. They set a "buy" rating and a $4.00 price target on the stock. D. Boral Capital restated a "buy" rating and set a $25.00 price target on shares of Humacyte in a research note on Monday, June 9th. Finally, Benchmark dropped their price target on Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Humacyte presently has an average rating of "Moderate Buy" and an average price target of $11.71.

Humacyte Stock Performance

HUMA traded down $0.04 on Friday, hitting $2.37. The company had a trading volume of 2,720,709 shares, compared to its average volume of 3,856,671. The stock has a fifty day moving average price of $1.91 and a 200-day moving average price of $3.16. Humacyte has a 12-month low of $1.15 and a 12-month high of $9.79. The stock has a market capitalization of $367.63 million, a price-to-earnings ratio of -1.77 and a beta of 2.00.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.09. The company had revenue of $0.52 million during the quarter, compared to analysts' expectations of $0.46 million. Analysts forecast that Humacyte will post -1.27 EPS for the current fiscal year.

Insider Activity at Humacyte

In related news, CFO Dale A. Sander purchased 20,000 shares of the firm's stock in a transaction on Thursday, April 10th. The stock was bought at an average cost of $1.53 per share, with a total value of $30,600.00. Following the completion of the acquisition, the chief financial officer now owns 40,600 shares of the company's stock, valued at $62,118. The trade was a 97.09% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Kathleen Sebelius purchased 50,000 shares of the firm's stock in a transaction on Tuesday, April 8th. The stock was bought at an average cost of $1.32 per share, with a total value of $66,000.00. Following the completion of the acquisition, the director now directly owns 91,207 shares of the company's stock, valued at $120,393.24. This trade represents a 121.34% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 83,993 shares of company stock worth $118,224 over the last quarter. Insiders own 5.10% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Vontobel Holding Ltd. acquired a new position in Humacyte in the fourth quarter valued at approximately $50,000. Petros Family Wealth LLC acquired a new position in Humacyte in the fourth quarter valued at approximately $50,000. Syon Capital LLC acquired a new position in Humacyte in the fourth quarter valued at approximately $54,000. Ameriprise Financial Inc. acquired a new position in Humacyte in the fourth quarter valued at approximately $58,000. Finally, Hsbc Holdings PLC acquired a new position in Humacyte in the fourth quarter valued at approximately $62,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.